Refractory mucosal candidiasis in advanced human immunodeficiency virus infection
Refractory mucosal candidiasis in advanced human immunodeficiency virus infection
复制标题
DOI：
10.1086/313765
复制
发表时间：
2000-05-01
影响因子：
11.8
通讯作者：
Powderly, WG
中科院分区：
文献类型：
--
作者：
Fichtenbaum, CJ;Koletar, S;Powderly, WG
我们对 1994-1996 年间 832 名晚期人类免疫缺陷病毒 (HIV) 感染者（中位 CD4 细胞计数，14/mm(3)）进行了一项多中心、前瞻性研究，研究了氟康唑难治性粘膜念珠菌病 (FRMC) 的危险因素、自然史和结果，FRMC 被定义为粘膜念珠菌病，尽管每日剂量（大于或等于200 mg）的氟康唑，36 人（4.3%）患有 FRMC（35 人，口服；1 人，食道），发病率为 4.2 每 100 人年（总随访年数 859.7）。在多变量模型中，入组后 6 个月内使用甲氧苄啶-磺胺甲恶唑（相对风险 [RR]，2.39；P = .04）以及每天或每隔一天使用氟康唑（RR，5.64；P = .004）与 FRMC 的发生显着相关。发生 FRMC 后的中位生存期为 32.6 周。总之，FRMC 的年发病率为
We conducted a multicenter, prospective study of the risk factors, natural history, and outcome of fluconazole-refractory mucosal candidiasis (FRMC) in 832 persons with advanced human immunodeficiency virus (HIV) infection (median CD4 cell count, 14/mm(3)) during 1994-1996, FRMC was defined as mucosal candidiasis that failed to resolve despite 14 days of therapy with daily doses (greater than or equal to 200 mg) of fluconazole, Thirty-six persons (4.3%) had FRMC (35, oral; 1, esophageal), for an incidence of 4.2 per 100 person-years (859.7 total years of follow-up). In a multivariate model, the use of trimethoprim-sulfamethoxazole within 6 months of enrollment (relative risk [RR], 2.39; P = .04) and the use of fluconazole daily or every other day (RR, 5.64; P = .004) were significantly associated with the development of FRMC. The median survival after the development of FRMC was 32.6 weeks. In conclusion, the annual incidence of FRMC was